Prothena reported financial results for the 4th quarter and full year 2024. The Company also provided business highlights and 2025 financial guidance.
Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback